Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myelomaJames R Berenson, Ori Yellin, Ravi Patel, et al.
Transfusion|April 25, 2023
Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapyMichael Kozak, Wesley Rubenstein, Derick Okwan-Duodu, et al.
Annals of Hematology|May 9, 2008
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-upJames R Berenson, Hank H Yang, Robert A Vescio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone lossJames R Berenson, Ori Yellin, Ralph V Boccia, et al.
European Journal of Haematology|February 20, 2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimenJames R Berenson, Ori Yellin, Donald Woytowitz, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 6, 2014
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myelomaJames R Berenson, Ori Yellin, Hesaraghatta K Shamasunder, et al.
Annals of Hematology|December 10, 2016
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomibAriana Berenson, Suzie Vardanyan, Michael David, et al.
Annals of Hematology|December 4, 2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinicAriana Berenson, Suzie Vardanyan, Michael David, et al.
British Journal of Haematology|November 23, 2017
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M Spektor, Laura Stampleman, et al.
British Journal of Haematology|November 16, 2012
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Ori Yellin, Alberto Bessudo, et al.
Pageof 2